1. Home
  2. SPRO vs ANTA Comparison

SPRO vs ANTA Comparison

Compare SPRO & ANTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$1.07

Market Cap

67.0M

Sector

Health Care

ML Signal

HOLD

Logo Antalpha Platform Holding Company Ordinary Shares

ANTA

Antalpha Platform Holding Company Ordinary Shares

HOLD

Current Price

$1.79

Market Cap

68.2M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPRO
ANTA
Founded
2013
2022
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Bankers/Brokers/Service
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
67.0M
68.2M
IPO Year
2017
2024

Fundamental Metrics

Financial Performance
Metric
SPRO
ANTA
Price
$1.07
$1.79
Analyst Decision
Buy
Strong Buy
Analyst Count
2
2
Target Price
$5.00
★ $8.25
AVG Volume (30 Days)
★ 461.5K
49.3K
Earning Date
11-12-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 111.81
N/A
EPS
N/A
★ N/A
Revenue
★ $66,802,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$38.46
P/E Ratio
★ N/A
$19.77
Revenue Growth
★ 39.24
N/A
52 Week Low
$1.08
$1.60
52 Week High
$3.08
$12.44

Technical Indicators

Market Signals
Indicator
SPRO
ANTA
Relative Strength Index (RSI) 39.23 30.63
Support Level N/A N/A
Resistance Level $1.28 $4.19
Average True Range (ATR) 0.06 0.28
MACD -0.01 -0.01
Stochastic Oscillator 0.00 15.04

Price Performance

Historical Comparison
SPRO
ANTA

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About ANTA Antalpha Platform Holding Company Ordinary Shares

Antalpha Platform Holding Co provides financing, technology and risk management solutions to institutional and corporate customers in the crypto asset industry. The company operates through Antalpha Prime platform in the following areas: Supply chain financing and Technology and services. Its revenue prominently consists of technology financing fees charged on the supply chain loans.

Share on Social Networks: